HAIFA, Israel, November 2, 2020-- Nurami Medical, a medical device R&D company, which is developing a groundbreaking technology that facilitates post-surgical healing of soft tissue healing, has announced that it has completed a fundraising round of up to $6 million. The financing will be used to fund completion of the ongoing clinical trial for Nurami's first product, ArtiFascia, intended for healing and repair of the dura following cranial neurosurgery, and to fund regulatory approval processes from the FDA and the CE.